Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Versicor Inc. (NasdaqNM:VERS)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug  9Earnings Announcement
Location
34790 Ardentech Court
Fremont, CA 94555
Phone: (510) 739-3000
Fax: (510) 739-3003
Email: info@versicor.com
Employees (last reported count): 41
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 60%
·Institutional: 25% (63% of float)
(52 institutions)
·Net Inst. Buying: 937.0K shares (+13.88%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Versicor Incorporated is a biopharmaceutical company focused on the marketing, development and discovery of pharmaceutical products for the treatment of bacterial and fungal infections. The Company's lead product candidate, V-Echinocandin (anidulafungin), is an antifungal intended for the intravenous treatment of serious systemic fungal infections. V-Echinocandin has potent fungicidal activity, a broad spectrum of activity against candida and aspergillus, low potential for developing resistance and a novel mechanism of action. The Company's second product candidate, V-Glycopeptide (dalbavancin), is a second generation antibiotic belonging to the same class as Vancomycin and is intended for the treatment of serious systemic infections, particularly staphylococci. V-Glycopeptide has potent bactericidal effect.
More from Market Guide: Expanded Business Description

Financial Summary
VERS is a biopharmaceutical company focused on the marketing, development and discovery of pharmaceutical products for the treatment of bacterial and fungal infections. For the six months ended 6/30/01, revenues increased 17% to $3.3 million. Net loss applicable to Common increased 51% to $13.8 million. Revenues reflect increased collaborative R&D funding. Net loss reflects increased R&D expenses due to an increase in clinical expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

David Milligan, Ph.D., 60
Chairman
--  --  
George Horner III, 56
Pres, CEO, Director
$346K--  
Richard White, Ph.D., 58
Exec. VP, CSO
438K$540K
Timothy Henkel, M.D., Ph.D.
Exec. VP and CMO
--  --  
Dov Goldstein, M.D., 32
VP-Fin., CFO
111K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VERSAs of 31-Aug-2001
Price and Volume
52-Week Low
on 18-Dec-2000
$5.75 
Recent Price$15.45 
52-Week High
on 8-Sep-2000
$16.313
Daily Volume (3-month avg)75.3K
Daily Volume (10-day avg)61.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change+12.4%
52-Week Change
relative to S&P500
+50.7%
Share-Related Items
Market Capitalization$356.6M
Shares Outstanding23.1M
Float9.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.02 
Earnings (ttm)-$1.17 
Earnings (mrq)-$0.38 
Sales (ttm)$0.31 
Cash (mrq)$3.22 
Valuation Ratios
Price/Book (mrq)5.11 
Price/EarningsN/A 
Price/Sales (ttm)50.42 
Income Statements
Sales (ttm)$6.36M
EBITDA (ttm)-$26.1M
Income available to common (ttm)-$23.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-28.83%
Return on Equity (ttm)-45.53%
Financial Strength
Current Ratio (mrq)10.04 
Debt/Equity (mrq)0.06 
Total Cash (mrq)$74.3M
Short Interest
As of 8-Aug-2001
Shares Short36.0K
Percent of Float0.4%
Shares Short
(Prior Month)
70.0K
Short Ratio0.44 
Daily Volume81.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.